Pulmonary Arterial Hypertension Market Overview
Pulmonary arterial hypertension is a life-threatening condition which gets worse over time but the treatments have helped the symptoms, such as, shortness of breath, chest pain, fatigue, etc., so that one can live better with the disease. Having pulmonary arterial hypertension also known as, PAH means that one has high blood pressure in their arteries that go from the heart to the lungs. It is quite different from having regular high blood pressure.
With pulmonary arterial hypertension, the tiny arteries in the lungs become narrow or blocked. It gets harder for blood to flow through them, which raises the blood pressure in the lungs. The heart has to work harder to pump blood through the arteries but after a while, the heart muscle gets weak, which can lead to heart failure. The main symptom is shortness of breath when the body is active. It usually starts slowly but gets worse as time goes on.
Pulmonary Arterial Hypertension market is currently valued at USD 7.36 billion and is expected to grow at a CAGR of 5.2% over the forecast period of 2022-2030.
Key market trends- Growth determinants and Challenges
The pulmonary arterial hypertension market growth is being fuelled by factors such as, high prevalence of PAH, adoption rate, availability of reimbursement, and entry of generics. The existence of a large geriatric population who have lower levels of immunity is prone to PAH and diseases associated with it. It is one of a high impact-rendering factor for the growth of the market over the forecast period. Though the beginning age for pulmonary arterial hypertension is 45 years, but it is often observed to occur in a population over 60 years of age.
Additionally, government initiatives, such as, Rare Disease Act 2002 and the Orphan Drug Act (ODA) are also expected to drive the market growth over the forecast period. These initiatives have promoted the ethical usage of orphan drugs.
On the flipside, the high price for the treatment of the pulmonary arterial hypertension disease can hamper the growth of the market.
Request a Free Sample Copy:https://wemarketresearch.com/sample-request/pulmonary-arterial-hypertension-market/78/
Segmental analysis of the market
Based on drug class
- Prostacyclin and Prostacyclin Analogs
- Soluble Guanylate Cyclase (SGC) Stimulators
- Endothelin Receptor Antagonist (ERA)
- Phosphodiesterase 5 (PDE-5)
Prostacyclin and Prostacyclin analogs segmented is expected to drive the lucrative growth of the market. This is because the sale of these drugs are expected to grow sharply in the future because of the growth in oral prostacyclin agents.
Based on type
- Branded
- Generics
The branded segment is expected to dominate the PAH market growth over the forecast years. This is because of the expiry of key patents, rise in launch of generics, and also growing consumption in developing markets.
North America is expected to amplify at a considerable CAGR
NORTH AEMRICA, EUROPE, ASIA PACIFIC, MIDDLE EAST AND AFRICA are the major regions constituting the geographical landscape of the worldwide Pulmonary Arterial Hypertension Market. Among these, North America is expected to amplify at a considerable CAGR and has the largest revenue share in the market. This is because of the developed healthcare infrastructure that has facilitated access to advanced therapeutics.
Competitive Landscape
The prominent players influencing the competitive hierarchy of the market sphere are United Therapeutics Corporation, Bayer, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc. (Novartis), Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd.
Purchase this Report: https://wemarketresearch.com/purchase/pulmonary-arterial-hypertension-market/78/?license=single
Major Developments
- Viatris Inc., has offered a robust portfolio of biosimilar, branded and complex generics, over-the-counter products that includes the PAH drug, Revatio.
- In 2020 and 2021, Gilead Sciences, Inc. has reported a decline in Letairis sales because of continued competition from generics. This was after the product lost exclusivity in 2019.
Major questions answered in this report
- What is the growth rate of Pulmonary Arterial Hypertension market?
- What are the primary growth determinants of Pulmonary Arterial Hypertension market?
- Which are the major regions constituting the geographical landscape of the market?
- Which are the prominent companies operating in the market?
Key takeaways from the report
- Pulmonary Arterial Hypertension market is projected to register at a CAGR of 5.2% over the forecast period of 2022-2030.
- High prevalence of PAH, adoption rate, availability of reimbursement, and entry of generics are aiding market progression.
- Branded segment is poised to expand significantly in the market.
- North America is anticipated to record notable gains because of the rise in healthcare expenditure.
About We Market Research
We Market Research is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. We Market Research is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
Contact Us:
We Market Research
Phone: +1(650)-666-4592
Email: [email protected]
Web: https://wemarketresearch.com/
